Medicine & Life Sciences
HIV
100%
Virus Diseases
57%
HIV Infections
54%
Hepacivirus
53%
Retroviridae Infections
52%
Opportunistic Infections
50%
Therapeutics
37%
Chronic Hepatitis C
37%
Pharmaceutical Preparations
35%
Anti-Retroviral Agents
26%
Tuberculosis
24%
Protease Inhibitors
24%
Reverse Transcriptase Inhibitors
23%
Ribavirin
20%
HIV-1
19%
Infections
18%
Antiviral Agents
17%
Coronavirus
17%
Acquired Immunodeficiency Syndrome
16%
Interferons
15%
Drug Interactions
14%
Congresses
14%
Human Influenza
14%
dolutegravir
13%
CD4 Lymphocyte Count
12%
Highly Active Antiretroviral Therapy
12%
Safety
11%
Placebos
11%
United States Food and Drug Administration
11%
Clinical Trials
11%
Cobicistat
11%
Sofosbuvir
10%
Systematized Nomenclature of Medicine
10%
Genotype
10%
Tenofovir
10%
tipranavir
10%
HIV Integrase Inhibitors
9%
JTK 303
9%
Osteomyelitis
9%
sofosbuvir drug combination ledipasvir
9%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
9%
RNA Replicase
9%
Pre-Exposure Prophylaxis
9%
BMS-790052
9%
Drug Evaluation
9%
telaprevir
9%
Randomized Controlled Trials
8%
Rilpivirine
8%
Viruses
8%